Halozyme Therapeutics Inc Cash Flow Conversion Efficiency
Halozyme Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Halozyme Therapeutics Inc (HALO) has a cash flow conversion efficiency ratio of 0.354x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($178.60 Million) by net assets ($503.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HALO market cap for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Halozyme Therapeutics Inc (2001–2024)
Cash flow conversion efficiency of Halozyme Therapeutics Inc from 2001 to 2024. This chart illustrates how Halozyme Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HALO share price today for real-time trading data and today's change.
Halozyme Therapeutics Inc Cash Flow Conversion Ratio Explained
Halozyme Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Halozyme Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Halozyme Therapeutics Inc ranked by their cash flow conversion efficiency. Review HALO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harmony Gold Mining Co. Ltd.
JSE:HAR
|
0.262x |
|
Alstom S.A.
PA:ALO
|
-0.053x |
|
IREN Ltd
NASDAQ:IREN
|
0.029x |
|
Storebrand ASA
OL:STB
|
0.363x |
|
Procore Technologies Inc
NYSE:PCOR
|
0.069x |
|
Anhui Tongguan Copper Foil Group Co. Ltd.
SHE:301217
|
N/A |
|
Shanghai International Airport Co Ltd
SHG:600009
|
0.041x |
|
Pharmaron Beijing Co Ltd
SHE:300759
|
0.068x |
Annual Cash Flow Conversion Efficiency for Halozyme Therapeutics Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Halozyme Therapeutics Inc from 2001 to 2024. Also see Halozyme Therapeutics Inc total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $363.82 Million | $479.06 Million | 1.317x | -71.60% |
| 2023-12-31 | $83.81 Million | $388.57 Million | 4.636x | +227.87% |
| 2022-12-31 | $169.80 Million | $240.11 Million | 1.414x | -6.99% |
| 2021-12-31 | $196.95 Million | $299.44 Million | 1.520x | +314.12% |
| 2020-12-31 | $151.05 Million | $55.45 Million | 0.367x | +139.44% |
| 2019-12-31 | $91.77 Million | $-85.42 Million | -0.931x | -368.05% |
| 2018-12-31 | $248.89 Million | $-49.50 Million | -0.199x | -130.91% |
| 2017-12-31 | $208.37 Million | $134.05 Million | 0.643x | -58.52% |
| 2016-12-31 | $-32.48 Million | $-50.38 Million | 1.551x | +279.86% |
| 2015-12-31 | $43.00 Million | $-37.08 Million | -0.862x | +24.95% |
| 2014-12-31 | $41.35 Million | $-47.52 Million | -1.149x | -146.56% |
| 2013-12-31 | $-19.99 Million | $-49.34 Million | 2.468x | +287.44% |
| 2012-12-31 | $48.85 Million | $-64.33 Million | -1.317x | +58.22% |
| 2011-12-31 | $10.90 Million | $-34.35 Million | -3.151x | -41.31% |
| 2010-12-31 | $20.35 Million | $-45.39 Million | -2.230x | +61.65% |
| 2009-12-31 | $6.90 Million | $-40.15 Million | -5.816x | -152.86% |
| 2008-12-31 | $15.38 Million | $-35.37 Million | -2.300x | -89880.87% |
| 2007-12-31 | $57.77 Million | $-147.66K | -0.003x | -100.83% |
| 2006-12-31 | $23.08 Million | $7.08 Million | 0.307x | +142.97% |
| 2005-12-31 | $18.21 Million | $-13.00 Million | -0.714x | -37.11% |
| 2004-12-31 | $14.82 Million | $-7.72 Million | -0.521x | +89.46% |
| 2003-12-31 | $10.06K | $-49.73K | -4.942x | -669.13% |
| 2002-12-31 | $86.81K | $-55.78K | -0.642x | +57.31% |
| 2001-12-31 | $22.84K | $-34.37K | -1.505x | -- |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more